ENDOMETRIN (progesterone) by Ferring Pharmaceuticals. Approved for progesterone [epc]. First approved in 2007.
Drug data last refreshed 4h ago · AI intelligence enriched 5d ago
ENDOMETRIN is a vaginal progesterone insert approved in 2007 for progesterone replacement therapy in reproductive endocrinology. It delivers micronized progesterone directly to the uterus via a vaginal insert formulation, supporting endometrial secretion and pregnancy maintenance. The drug is indicated for progesterone supplementation in patients undergoing assisted reproductive technology and other fertility-related conditions.
Product is nearing loss of exclusivity with minimal Part D spending ($8K in 2023), signaling a small, mature commercial footprint with limited team expansion opportunities.
Progesterone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Individualized Prolonged Luteal Support After Fresh Embryo Transfer in Women With Low Progesterone
Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert
Exogenous Progesterone as Ovulation Trigger
Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Worked on ENDOMETRIN at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moENDOMETRIN currently has zero linked job openings and limited commercial presence, reflecting its mature lifecycle stage and approaching loss of exclusivity. Career opportunities on this product are constrained, making it suitable for professionals seeking stable, niche expertise in fertility therapeutics rather than growth-driven roles.